Generic OTC Lamisil approved
This article was originally published in The Tan Sheet
Executive Summary
FDA on July 2 approves Taro Pharmaceutical U.S.A's application for a generic version of Novartis' OTC athlete's foot cream Lamisil AT (terbinafine hydrochloride, 1 percent). Taro's product will be the first generic Lamisil cream on the market, according to FDA. The firm was granted tentative approval in March 2006 (1"The Tan Sheet" March, 27, 2006, p. 11). Novartis recently introduced a gel form, Lamisil AT Gel Advanced, which "cures most athlete's foot with 1/2 the applications of any other product," according to the product Web site. FDA also approved the first generic versions of Rx Lamisil tablets as the remaining patent or exclusivity for the drug expired June 30...
You may also be interested in...
Taro Granted Tentative Approval For First Lamisil Cream Equivalent
Taro Pharmaceuticals has received what appears to be the first tentative approval in the U.S. for a generic version of Novartis' OTC antifungal cream Lamisil, the Israeli firm announced March 23
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.